CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


AcalabrutinibWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)


Name (Synonyms) Correlation

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D058186 Acute Kidney Injury NIH 0.45
D014947 Wounds and Injuries NIH 0.41

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 A Phase 2 Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19

ACE-ID- 201 will investigate the safety, efficacy and pharmacokinetics of acalabrutinib together with Best Supportive Care in the treatment of COVID-19.

NCT04346199 COVID-19 Drug: Acalabrutinib

Primary Outcomes

Description: Treatment failure rate, where treatment failure is defined as use of assisted ventilation or death.

Measure: Treatment failure rate

Time: Approximately 30 days

Secondary Outcomes

Measure: Number of days alive free of assisted ventilation

Time: Approximately 30 days

Measure: Number of days with assisted ventilator use

Time: Approximately 30 days

Measure: Number of days hospitalized

Time: Approximately 30 days

Measure: Number of days in ICU

Time: Approximately 30 days

Measure: Number of days alive outside of hospital

Time: Approximately 30 days

Measure: Number of days alive outside of hospital

Time: Approximately 90 days

Measure: Occurrence of Adverse Events and Serious Adverse Events

Time: Approximately 30 days

Description: Peak Plasma Concentration (Cmax)

Measure: Pharmacokinetics of acalabrutinib and its active metabolite ACP-5862 (Cmax)

Time: Approximately 30 days

Description: Time to Maximum Concentration (Tmax)

Measure: Pharmacokinetics of acalabrutinib and its active metabolite ACP-5862 (Tmax)

Time: Approximately 30 days

Description: Area under the plasma concentration versus time curve (AUC)

Measure: Pharmacokinetics of acalabrutinib and its active metabolite ACP-5862 (AUC)

Time: Approximately 30 days


No related HPO nodes (Using clinical trials)